EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Vericiguat Enhances Olfactory Function in Post-Infectious Anosmia: A Randomized Pilot Double-Blind Placebo-Controlled Trial

Adnan Alharbi iD, Mohamed H Abdelazim iD, Abdullah S Alshammari iD, Majed A Algarni iD, Abdulaziz Ibrahim Alzarea iD, Fahad H Baali iD, Abdullah H Altemani iD, Ahmed H Abdelazim iD

American Journal of Rhinology & Allergy · 2025

DOI: 10.1177/19458924251364571 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Rhinology & Allergy, 2025. Verfasst von Adnan Alharbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. Hauptthemen laut MEDLINE: Anosmia, Respiratory Tract Infections, Smell, Pyrimidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Taif University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Olfactory dysfunction affects approximately 29% of the population and has a profound impact on quality of life. It frequently follows upper respiratory tract infections and lacks effective pharmacological treatments. Vericiguat, a soluble guanylate cyclase stimulator that increases intracellular cyclic guanosine monophosphate, is approved for heart failure and has potential neuro-modulatory effects relevant to olfactory processing.

Objective

This pilot study investigates the efficacy of oral vericiguat in improving olfactory function in patients with persistent anosmia following upper respiratory tract infections.

Methods

In a double-blind, randomized controlled trial, 88 participants with post-infectious anosmia were assigned to receive either placebo (n = 44) or vericiguat (4 mg, twice daily; n = 44) for 12 months. Olfactory function was assessed monthly using the Sniffin’ Sticks test, measuring Threshold (T), Discrimination (D), and Identification (I) scores. Data were analyzed using repeated-measures ANOVA and post-hoc Bonferroni corrections.

Results

At baseline, all olfactory scores were similar between groups. In the vericiguat group, T scores increased from 3.84 ± 0.19 to 4.65 ± 0.20 (P = 0.003), D scores from 8.25 ± 0.65 to 9.20 ± 0.86 (P = 0.008), and I scores from 7.34 ± 0.72 to 8.62 ± 0.79 (P = 0.008). No significant changes were observed in the placebo group. Between-group differences became statistically significant for D at month 4 (P < 0.05), T at month 6 (P < 0.05), and I at month 7 (P < 0.05). However, the mean total TDI improvement in the vericiguat group (+ 3.19) did not reach the clinical threshold of 5.5 points.

Conclusion

Vericiguat significantly improved olfactory threshold, discrimination, and identification scores compared to placebo. These findings highlight its potential as a pharmacological option for olfactory dysfunction, although the clinical magnitude of benefit remains below the established threshold. Further studies should explore mechanisms and broader clinical applications.

Trial registration

DFM-IRB00012367–23-07-008.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnosmiaRespiratory Tract InfectionsSmellPyrimidinesOlfaction DisordersHumansDouble-Blind MethodMalePilot ProjectsFemaleMiddle AgedAdultAgedTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

Sniffin’ Sticks testcGMPdiscriminationidentificationnitric oxide signalingolfactory dysfunctionrandomized controlled trialsoluble guanylate cyclasethresholdvericiguat

Substanzen

Pyrimidines

Autor:innen und Institutionen

  • Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Otolaryngology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
  • Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia.
  • Clinical Pharmacy Department, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
  • Department of Family and Community Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
  • Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Adnan Alharbi, Mohamed H Abdelazim, Abdullah S Alshammari, Majed A Algarni, Abdulaziz Ibrahim Alzarea, Fahad H Baali, Abdullah H Altemani, Ahmed H Abdelazim

Förderung

  • Taif University

Zitieren

APA

Alharbi, A., Abdelazim, M. H., Alshammari, A. S., Algarni, M. A., Alzarea, A. I., Baali, F. H., Altemani, A. H., & Abdelazim, A. H. (2025). Vericiguat Enhances Olfactory Function in Post-Infectious Anosmia: A Randomized Pilot Double-Blind Placebo-Controlled Trial. American Journal of Rhinology & Allergy. https://doi.org/10.1177/19458924251364571

Vancouver

Alharbi A, Abdelazim MH, Alshammari AS, Algarni MA, Alzarea AI, Baali FH, et al. Vericiguat Enhances Olfactory Function in Post-Infectious Anosmia: A Randomized Pilot Double-Blind Placebo-Controlled Trial. American Journal of Rhinology & Allergy. 2025. doi:10.1177/19458924251364571

BibTeX
@article{Alharbi2025,
  author = {Alharbi, Adnan and Abdelazim, Mohamed H and Alshammari, Abdullah S and Algarni, Majed A and Alzarea, Abdulaziz Ibrahim and Baali, Fahad H and Altemani, Abdullah H and Abdelazim, Ahmed H},
  title = {Vericiguat Enhances Olfactory Function in Post-Infectious Anosmia: A Randomized Pilot Double-Blind Placebo-Controlled Trial},
  journal = {American Journal of Rhinology & Allergy},
  year = {2025},
  doi = {10.1177/19458924251364571}
}
Kostenlos starten →